• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

达托霉素血浆浓度的UPLC-MS/MS法测定及其在重症患者体内药代动力学

胡琳璘, 郭楠, 张学丽, 邵华

胡琳璘, 郭楠, 张学丽, 邵华. 达托霉素血浆浓度的UPLC-MS/MS法测定及其在重症患者体内药代动力学[J]. 中国药科大学学报, 2015, 46(6): 700-706. DOI: 10.11665/j.issn.1000-5048.20150611
引用本文: 胡琳璘, 郭楠, 张学丽, 邵华. 达托霉素血浆浓度的UPLC-MS/MS法测定及其在重症患者体内药代动力学[J]. 中国药科大学学报, 2015, 46(6): 700-706. DOI: 10.11665/j.issn.1000-5048.20150611
shu
HU Linlin, GUO Nan, ZHANG Xueli, SHAO Hua. Determination of daptomycin by UPLC-MS/MS and its pharmacokinetic eva-luation in critically ill patients[J]. Journal of China Pharmaceutical University, 2015, 46(6): 700-706. DOI: 10.11665/j.issn.1000-5048.20150611
Citation: HU Linlin, GUO Nan, ZHANG Xueli, SHAO Hua. Determination of daptomycin by UPLC-MS/MS and its pharmacokinetic eva-luation in critically ill patients[J]. Journal of China Pharmaceutical University, 2015, 46(6): 700-706. DOI: 10.11665/j.issn.1000-5048.20150611
shu

达托霉素血浆浓度的UPLC-MS/MS法测定及其在重症患者体内药代动力学

  • 1.

    东南大学附属中大医院药学部

  • 2.

    中国药科大学药学院

基金项目: 南京药学会-常州四药医院药学科研基金资助项目(No.2015YX004)

Determination of daptomycin by UPLC-MS/MS and its pharmacokinetic eva-luation in critically ill patients

摘要

    摘要
  • 摘要: 建立测定血浆和置换液中达托霉素的高通量UPLC-MS/MS方法，采用Kinetex C18色谱柱(50 mm×2.1 mm，1.7 μm)，柱温45 ℃，流动相为含0.1%甲酸水溶液-乙腈，流速0.4 mL/min，电喷雾离子化正离子扫描模式下，达托霉素m/z 810.9→159.1；内标来曲唑m/z 286.2→217.2，分析时长2.5 min。达托霉素在血浆(1~200 μg/mL)和置换液(0.005~20 μg/mL)中均呈现良好的线性关系，日内及日间精密度、准确度、稳定性等均符合生物样品测定要求。静脉滴注6 mg/kg达托霉素在接受持续肾脏替代治疗(CRRT)治疗的感染性休克患者体内的cmax和AUC0-24明显低于健康受试者，下降比例分别为50%和60%，未达到预期的杀菌效果。这可能与感染性休克患者毛细血管通透性增加联合间隙水肿，从而使药物的分布容积增加有关，此外，肾脏替代治疗模式可体外滤过约16%的达托霉素，导致剂量不足和感染治疗不彻底。研究结果推荐在接受CRRT治疗的感染性休克患者中使用达托霉素应适当增加剂量，且须对该类患者进行达托霉素治疗药物浓度监测。
    Abstract: A sensitive, selective and simple liquid chromatography tandem mass spectrometry(UPLC-MS/MS)method was developed for determining of daptomycinin human plasma and effluent. The analyte was extracted from plasma samples by SPE method, separated through a Phenomenex Kinetex C18 column(50 mm×2. 1 mm, 1. 7 μm)using isocratic mobile phase consisting of 0. 1% formic acid-acetonitile(75 ∶25), and analyzed by electro-spray ionization(ESI). The precursor to product ion transitions of m/z 810. 9→159. 1 and m/z 286. 2→217. 2 were used to measure daptomycinand the internal standard, respectively. The method was validated over a concentration range(plasma: 1-200 μg/mL, effulent: 0. 005-20 μg/mL). The intra- and inter-day precision values were less than 10% and accuracy values 90%-110%. The stability of daptomycinin human plasma and effluent under different storage conditions met the requirements of bioanalytical method. The concentration of daptomycin is significant lower in the septic shock patient, when give a dose of 6 mg/kg, the cmax and AUC0-24 h of steady state decreased by 50% and 60% respectively; the increase in capillary permeability and interstitial oedema during sepsis and septic shock may enhance drug distribution. By the way, daptomycin can be cleared via continuous veno-venous hemofiltration(CVVH)for nearly 16%. In summary, on the treatment of continuous renal replacement therapy(CRRT)in patients with septic shock with daptomycin therapy, the suggested dose should be increased, and the drug monitoring should be carried on.
    • HTML全文
    • 参考文献(18)
  • [1] Tally FP,Zeckel M,Wasilewski MM.Daptomycin:a novel agent for grampositiveinfections [J].Expert Opin Investig Drugs,1999,8(8):1223-1238.
    [2] Reyes J,Panesso D,Tran TT,et al.A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis [J].Infect Dis,2015,211(8):1317-1325
    [3] Dellinger RP,Levy MM,Rhodes A,et al.Surviving sepsis campaign:international guidelines for management of severe sepsis and septic shock,2012 [J].Intensive Care Med,2013,39(2):165-228.
    [4] Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically Ill adult patients receiving continuous renal replacement therapy [J].Clin Infect Dis,2005,41(8):1159-1566.
    [5] Dvorchik B,Moderate liver impairment has no influence on daptomycin pharmacokinetics [J].Clin Pharmacol,2004,44(7):715-722.
    [6] Tobin CM,Darville JM,Lovering AM,et al.An HPLC assay for daptomycin in serum [J].Antimicrob Chemother,2008,62:1462-1476.
    [7] Lorena B,Antonio DA,Simone P,et al.Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots [J].Pharm Biomed Anal,2014,88:66-70.
    [8] Rauh M.LC-MS/MS for protein and peptide quantification in clinical chemistry [J].Chromatogr B Analyt Technol Biomed Life Sci,2012,883- 884:59-67.
    [9] Marie CV,Danie BF,Olivier T,et al.Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry [J].Clin Chem Lab Med,2011,49:69-75.
    [10] Gika HG,Michopoulos F,Divanis DS,et al.Daptomycin determination by liquid chromatography-mass spectrometry in peritoneal fluid,blood plasma,and urine of clinical patients receiving peritoneal dialysis treatment [J].Anal Bioanal Chem,2010,397:2191-2197.
    [11] Fotini NB,Evangelos G,Athanasios S,et al.Development and validation of an ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of daptomycin in human plasma [J].Pharm Biomed Anal,2011,56:78-85.
    [12] Liu WY,Xu WL,Li P,et al.Tissue distribution and excretion of baicalein and its main metabolite in rats by LC-MS/MS [J].China Pharm Univ(中国药科大学学报),2009,40(4):348-352.
    [13] Jiao HY,Xu FG,Tian Y,et al.Determination of fluoroquinolones multiresidue in milk by solid-phase extraction-LC-MS/MS [J].China Pharm Univ(中国药科大学学报),2009,40(1):62-66.
    [14] Tian Y,Zhang ZJ,Li J,et al.Multiresidue determination of fluoroquinolones in eggs by solid-phase extraction-LC-MS/MS [J].China Pharm Univ(中国药科大学学报),2010,41(1):60-65.
    [15] Dvorchik BH,Brazier D,DeBruin MF,et al.Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects [J].Antimicrob Agents Chemother,2003,(47):1318-1323.
    [16] Mark B,David PB,Sara Y.Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].Antimicrob Agents Chemother,2006,50(10):3245-3249.
    [17] Roberts JA,Lipman J.Pharmacokinetic issues for antibiotics in the critically ill patient [J].Critical Care Medicine,2009,37(3):840-851;859.
    [18] Nasia S,David A,Craig WA.In vivo pharmacodynamic activity of daptomycin [J].Antimicrob Agents Chemother,2004,48(1):63-68.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1251
  • HTML全文浏览量:  1
  • PDF下载量:  1841
  • 被引次数: 0
出版历程
  • 刊出日期:  2015-12-24

目录

摘要
HTML全文
    参考文献(18)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：365358

    x 关闭 永久关闭